Regulatory Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy Pharmaceutical TechnologyPfizer and Astellas have received FDA acceptance for priority review of their sBLA for perioperative Padcev combined with Keytruda for MIBC.RegulatoryOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaceutical Technology Pfizer and Astellas have received FDA acceptance for priority review of their sBLA for perioperative Padcev combined with Keytruda for MIBC. RegulatoryOncologyRead full story Post navigation Previous: Italy leads the way on child genetic disease diagnosisNext: Asahi Kasei acquires German company Aicuris Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
